TY  - BOOK
AU  - Agam,G.
AU  - Amrani,H.L.
AU  - Armstrong,D.J.
AU  - Assouline,Z.
AU  - Baba,M.
AU  - Balconi,G.
AU  - Belew,M.
AU  - Bertina,R.M.
AU  - Blohn,G.von
AU  - Blombäck,B.
AU  - Caen,J.
AU  - Carrell,N.
AU  - Chang,G.
AU  - Comeau,C.M.
AU  - Courtois,G.
AU  - Crabtree,G.R.
AU  - Dauden,V.M.
AU  - Deguchi,K.
AU  - Dejana,E.
AU  - Dunn,F.
AU  - Eisenhut,M.
AU  - Fasold,H.
AU  - Fowlkes,D.M.
AU  - Francis,J.L.
AU  - Galanakis,D.K.
AU  - Godal,H.C.
AU  - Gollwitzer,R.
AU  - Graeff,H.
AU  - Haber,E.
AU  - Hafter,R.
AU  - Harenberg,J.
AU  - Haverkate,F.
AU  - Hawiger,J.
AU  - Hellstern,P.
AU  - Hensc,A.
AU  - Henschen,A.
AU  - Hermann,H.-J.
AU  - Heymann,E.
AU  - Hoegee-de Nobel,B.
AU  - Holm,B.
AU  - Homandberg,G.A.
AU  - Hugo,R.von
AU  - Hui,K.Y.
AU  - Ireland,H.
AU  - Jelenska,M.
AU  - Kahn,A.
AU  - Kaiser,C.
AU  - Kaminski,M.
AU  - Klaubert,W.
AU  - Kloczewiak,M.
AU  - Kluft,C.
AU  - Koopman,J.
AU  - Kopec,M.
AU  - Lane,D.A.
AU  - Languino,L.R.
AU  - Lijnen,R.
AU  - Livne,A.
AU  - Lukas,T.J.
AU  - Luria,R.
AU  - Mannucci,P.M.
AU  - Marguerie,G.
AU  - Matsuda,M.
AU  - Matsueda,G.R.
AU  - McDonagh,J.
AU  - Mentlein,R.
AU  - Mihalyi,E.
AU  - Mirshahi,M.
AU  - Miyashita,C.
AU  - Morimoto,K.
AU  - Mosesson,M.W.
AU  - Mullis,N.T.
AU  - Müller-Berghaus,G.
AU  - Nakamikawa,C.
AU  - Nieuwenhuizen,W.
AU  - Ohlsson,K.
AU  - Peerschke,E.I.B.
AU  - Preissner,K.T.
AU  - Rochowska,M.
AU  - Rotker,J.
AU  - Saldeen,K.
AU  - Saldeen,T.
AU  - Samama,M.
AU  - Schwamborn,J.
AU  - Selmayr,E.
AU  - Seydewitz,H.H.
AU  - Shainoff,J.R.
AU  - Shoshani,L.
AU  - Simmonds,V.J.
AU  - Skurzak,H.
AU  - Soria,C.
AU  - Soria,J.
AU  - Southan,C.
AU  - Stehle,G.
AU  - Struckhoff,G.
AU  - Tanaka,K.
AU  - Thompson,E.
AU  - Timmons,S.
AU  - Traas,D.
AU  - Traas,D.W.
AU  - Uzan,G.
AU  - Verheijen,J.
AU  - Verheijen,J.H.
AU  - Voskuilen,M.
AU  - Vries,J.X.de
AU  - Waibel,S.
AU  - Wallin,R.
AU  - Watanabe,K.
AU  - Watson,N.J.
AU  - Wenzel,E.
AU  - Witt,I.
AU  - d’Angelo,A.
TI  - Fibrinogen. Proceedings/ Workshop on Fibrinogen. 
T2  - Fibrinogen. Proceedings/ Workshop on Fibrinogen
SN  - 9783110098068
PY  - 2019///]
CY  - Berlin, Boston : 
PB  - De Gruyter, 
KW  - SCIENCE / Life Sciences / Biochemistry
KW  - bisacsh
N1  - Frontmatter --; Preface --; Contents --; I. A HISTORICAL NOTE --; Two thousand years of fibrinogen research and evidence for fibrin being the first protein --; II. GENE ANALYSIS --; Fibrinogen evolution - The structure and evolution of fibrinogen: The coiled coil region --; Absence of gross defect of fibrinogen genes in one patient with congenital afibrinogenemia --; III. FIBRINOGEN-FIBRIN CONVERSION --; Fibrinogen to fibrin - an overview --; Fibrin - specific monoclonal antibodies are elicited by immunization with a synthetic fibrin-like peptide --; Enhancement of fibrin polymerization by active site - inhibited thrombin --; Peptides released from human fibrinogen by thrombic enzymes --; The analysis of fibrinopeptide release from S--carboxymethylated fibrinogen chains using high-performance liquid chromatography --; Moaification of the fibrin a-chain by dipeptidyl peptidase IV --; IV. FIBRINOGEN-FIBRIN INTERACTION --; Analysis of composition of soluble fibrinogen/fibrin complexes by differential ultracentrifugation --; Reversible interactions of fibrin and fibrinogen: an ultracentrifugation study --; V. NORMAL FIBRINOGEN VARIANTS --; Evidence that the amount of heparin precipitable fraction is influenced by fibrinogen quality --; The location of a second in vivo phosphorylation site in the Aa-chain of human fibrinogen --; Evidence that the y chain population of human platelet fibrinogen lacks the y' variant that is present in plasma fibrinogen --; Differences and similarities between human adult and fetal fibrinogen fragments D1 --; VI. ABNORMAL FIBRINOGEN VARIANTS --; Functional defects in abnormal fibrinogens --; Study of 10 cases of congenital dysfibrinogenemia: clinical and molecular biological aspects --; Fibrinogens Sydney I and II, a kinetic study of (His16 )FPA cleavage and its effect on FPB cleavage --; Fibrinogens London I - IV, Manchester, Sydney I and II. Cleavage of fibrinopeptides by thrombin and expression of their polymerisation abnormalities --; Aspects of evaluation of fibrinogen Stony Brook - A defect resulting in failure to release fibrinopeptide A --; Fibrinogen Tokyo II: An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules --; Fibrinogen Milan II: A congenital dysfibrinogenemia with a defective clotting by thrombin, normal clotting by arvin, reptilase and prothrombin-staphy1ocoagulase complex, associated with thrombotic episodes --; Preliminary report concerning two new cases of congenital dysfibrinogenemia (Homburg II and Homburg III) --; The effect of sodium citrate on fibrin polymerisation in patients with liver disease --; VII. FIBRINOGEN DEGRADATION PRODUCTS --; Studies of the proteolytic fragments of the C-terminal portion of the a-chain of human fibrinogen --; Biodistribution or human fibrinogen-derived peptides in rabbits --; Structure-function studies on a vasoactive pentapeptide derived from plasm in degradation of human fibrin(ogen) --; Purification and characteristics of a vasoactive peptide derived from elastase degradation of human fibrin(ogen) --; Relation of crosslinked to non crosslinked fibrin derivatives in tumor ascites compared to cirrhosis ascites --; VIII. INTERACTION WITH PLASMINOGEN AND ITS ACTIVATOR --; Study of the interaction between plasminogen and fibrinogen degradation products using immunoenzymological assay --; Fibrin and plasminogen structures involved in the tissue-type plasminogen activator catalyzed activation of plasminogen --; Kinetics of the tissue-type plasminogen activatormediated activation of plasminogen. Influence of CNBr fibrin(ogen) fragment FCB-2 and different forms of plasminogen --; IX. INTERACTION WITH CELLS --; Structural characterization of the recognition site for platelet receptors on human fibrinogen --; Binding or fibrinogen to ADP-treated platelets: Importance of the Aα-chain --; Inhibition of fibrinogen binding to activated platelets by oligoamines --; Specific interaction between fibrinogen-fibrin and endothelial cells --; Influence of fibrin, fibrinogen and fibrinogen degradation products on cultured endothelial cells --; Interaction of fibrin with malignant melanoma cells in long term culture --; AUTHOR INDEX --; SUBJECT INDEX --; Backmatter; restricted access; Issued also in print
UR  - https://doi.org/10.1515/9783110855951
UR  - https://www.degruyter.com/isbn/9783110855951
UR  - https://www.degruyter.com/document/cover/isbn/9783110855951/original
ER  -